It is reasonable to speculate that “platinum-resistant” ovarian cancers with high RNR M2 levels may have a large S-phase population, escaping cisplatin-mediated cytotoxicity through enhanced repair of stalled forks formed at cisplatin-DNA adducts during S-phase DNA replication [32]. The gene discussed is NR2E3; the disease is ovarian carcinoma.